10x Genomics filed a lawsuit against Element Biosciences, alleging that Element’s Aviti24 multiomic analysis platform infringes multiple spatial technology patents licensed from Harvard University. The complaint was filed in the US District Court for the District of Delaware, with 10x seeking monetary damages, attorneys’ fees, and a permanent injunction. 10x cited specific patent numbers covering compositions and methods for analyte detection and methods for selectively sequencing amplicons. The company argued that the asserted Aviti24 system uses patented inventions, while Element said it strongly disagrees and believes the claims are without merit, framing the filing as part of a broader pattern of patent disputes. The case arrives as spatial workflows proliferate. Element has said it plans to launch direct in-tissue spatial sequencing products later this year across fresh-frozen and FFPE tissues, adding commercial stakes to an IP fight that could affect customers and platform strategies.